Convergence Investment Partners LLC Buys Shares of 9,228 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Convergence Investment Partners LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 9,228 shares of the medical equipment provider's stock, valued at approximately $741,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. UMB Bank n.a. lifted its holdings in shares of Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after buying an additional 247 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 208 shares during the period. Principal Securities Inc. purchased a new position in shares of Lantheus during the 4th quarter valued at about $28,000. Fidelis Capital Partners LLC purchased a new position in Lantheus in the 1st quarter worth approximately $34,000. Finally, FinTrust Capital Advisors LLC raised its holdings in shares of Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 232 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on LNTH. Redburn Atlantic started coverage on Lantheus in a research note on Tuesday. They set a "buy" rating and a $175.00 price target on the stock. Truist Financial cut their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Leerink Partners increased their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Finally, B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Activity

In other news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Insiders have sold a total of 41,193 shares of company stock worth $3,949,202 over the last 90 days. 1.50% of the stock is currently owned by company insiders.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $1.04 during midday trading on Tuesday, hitting $105.43. The company's stock had a trading volume of 592,722 shares, compared to its average volume of 1,045,903. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The firm has a market capitalization of $7.31 billion, a price-to-earnings ratio of 16.10 and a beta of 0.51. The stock has a fifty day moving average price of $101.14 and a 200 day moving average price of $80.60.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same period in the previous year, the business earned $1.40 EPS. The business's revenue was up 22.5% compared to the same quarter last year. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.03 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.